Oppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.Lam commented, "BLUE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE